Etelcalcetide for preserving vitamin K protein activity in dialysis patients
Part of Hormones & metabolism, Injuries & trauma clinical trials.
This study tests whether a drug called Etelcalcetide can help preserve the activity of vitamin K-dependent proteins in people on hemodialysis who have severe overactive parathyroid glands. It may help reduce calcium buildup in blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and on long-term hemodialysis (three times a week).
- Your parathyroid hormone (PTH) levels must be very high, over 500 pg/ml, on two recent blood tests.
- You should have moderate calcium buildup in your main blood vessels (aorta or iliac arteries) or mild calcium buildup in your heart valves.
- If you have used any oral calcimimetic drugs (like cinacalcet), you must have stopped them at least 30 days ago.
- You cannot have had a parathyroidectomy (surgery to remove parathyroid glands) in the last 6 months or be planning one soon.
- You must not have had certain bone diseases, uncontrolled thyroid problems, recent cancer, or be pregnant/nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a very high dose of vitamin D3 can reduce moderate to severe chronic pain in people on hemodialysis. It may help by improving vitamin D-related pathways that could affect pain, but you must also meet specific health and testing requirements.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This trial tests two different vitamin D medications (doxercalciferol and calcitriol) to see which one better controls a common problem in dialysis patients called secondary hyperparathyroidism, where the parathyroid gland overproduces a hormone. The goal is to find the safest and most effective treatment.
This trial tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. It may help control high parathyroid hormone levels when current treatments are not enough.
This trial checks if measuring vitamin D in dialysis patients can lead to better treatment, then gives vitamin D supplements to those who are low. It may help improve your bone and heart health.
Hear when a new Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.